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ANG II has been reported to inhibit several vascular K ϩ channels, including BK Ca channels in the coronary artery (25, 36) , K V channels in the rabbit portal vein (5), and K ATP channels in the rat mesenteric artery (15, 20) . The inhibition of K V current of the portal vein by ANG II involves activation of PKC (5), and we have shown that a component of the action of ANG II on K ATP current in the mesenteric artery also occurs via this pathway (15, 20) . However, we also showed that a substantial component of the inhibition of K ATP current by ANG II resulted from a reduction in steadystate channel activation by protein kinase A (PKA) (15) . Because K V channels of the rabbit portal vein and colonic smooth muscle are activated by PKA-induced phosphorylation (1, 19) , it is possible that a reduction in PKA activity could also contribute to the inhibitory effect of ANG II on K V current (I K V ).
In the present study, we investigated the mechanism by which ANG II inhibits I K V of rat mesenteric arterial smooth muscle by using conditions designed to minimize contamination from other currents. ANG II altered the kinetics of I K V by speeding up both activation and inactivation. We show that ANG II inhibits I K V via binding to AT 1 receptors and demonstrate for the first time that, as for K ATP channels, inhibition of K V occurs not only through activation of PKC but also by inhibition of PKA. Moreover, our results establish that PKC-⑀ is the subtype involved in the inhibition of K V channels.
METHODS
Preparation of vascular smooth muscle cells. Vascular smooth muscle cells from rat mesenteric arteries were dissociated as follows. Male adult Wistar rats were rendered unconscious by exposure to a rising concentration of CO 2 and killed by exsanguination. The care of the animal conformed to the requirements of the UK Animals (Scientific Procedures) Act of 1986.
Arteries were removed and cleaned of blood and connective tissue in ice-cold solution containing (in mM) 137 NaCl, 5.6 KCl, 0.42 Na 2HPO4, 0.44 NaH2PO4, 1 MgCl2, 2 CaCl2, 10 HEPES, and 10 glucose, adjusted with NaOH to pH 7.4. After dissection, the arteries were transferred to the same solution except that CaCl2 was reduced to 0.1 mM (low-calcium solution) for 10 min, and warmed to 35°C in a water bath. First, arteries were incubated for 30-35 min in low-calcium solution containing (in mg/ml) 0.9 albumin, 1.4 papain, and 0.9 dithioerythritol. The mesenteric artery was then further digested for 16-20 min in low-calcium solution containing (in mg/ml) 0.9 albumin, 1.4 collagenase type F (Sigma), and 0.9 hyaluronidase type I-S (Sigma). Arteries were then transferred to low-calcium solution containing albumin (1 mg/ml). Single smooth muscle cells were obtained by gentle trituration with a wide-bore pipette, stored at 4°C, and used on the day of preparation.
Solutions and chemicals. For conventional whole cell recordings, the intracelluar solution contained (in mM) 110 KCl, 30 KOH, 10 HEPES, 10 EGTA, 1 MgCl 2, 1 CaCl2, 3.0 Na2ATP, and 0.5 GTP, adjusted to pH 7.2. To minimize the activity of KATP channels, a high concentration of ATP (3.0 mM) was used. The free [Ca 2ϩ ], calculated using the program Maxchelator (http://www.stanford.edu/%7Ecpatton/maxc. html), was 20 nM. The 6 mM K ϩ extracellular solution contained (in mM) 134 NaCl, 6 KCl, 1 MgCl2, 0.1 CaCl2, 10 HEPES, and 10 glucose, adjusted to pH 7.4. To minimize the activity of BKCa channels, external Ca 2ϩ was lowered to 0.1 mM to reduce Ca 2ϩ influx, and intracellular Ca 2ϩ was buffered to a low level with EGTA. For single channel experiments, the pipette contained (in mM) 140 KCl, 10 HEPES, 1 CaCl2, and 1 MgCl2 (pH 7.4), and the bath solution contained (in mM) 110 KCl, 30 KOH, 10 EGTA, 10 HEPES, 1 MgCl2, and 1 Na2ATP (pH 7.2).
The external solution was changed by continuous perfusion of the experimental chamber (volume, 0.4 ml). ANG II and 1,2-dioctanyoyl-rac-glycerol (DiC8) were purchased from Sigma. Gö6976, Rp-adenosine 3Ј,5Ј-cyclic monophosphothioate, triethylammonium salt (Rp-cAMPS), PKA inhibitor peptide 5-24 (PKA-IP), myristoylated PKC inhibitor peptide 19-27 (PKC-IP), and PKC-⑀ translocation inhibitor peptide were obtained from Calbiochem. Losartan was kindly provided by Dr. A. Stanley, Department of Medicine, University of Leicester. DiC8 and Gö6976 were dissolved in DMSO. The final concentration of DMSO was Ͻ0.2%.
Data recording and analysis. Whole cell and single channel currents were recorded from single smooth muscle cells using the patch-clamp technique (13) . Currents were recorded using an Axopatch 200 amplifier (Axon Instruments). Patch pipettes were made from thin-walled borosilicate glass (Clark Electromedical) using a pp-83 vertical puller (Narishige; Tokyo, Japan) and coated with sticky wax (Kemdent) to reduce capacitance. Whole cell currents were filtered at 5 kHz, and single channel currents were filtered at 2 kHz (Ϫ3 dB). Electrode resistance before sealing was 3-5 M⍀ and after sealing was Ͼ10 G⍀. All experiments were done at 20-25°C.
Current-voltage (I-V) relations for steady-state current were measured at the end of 400-ms pulses to voltages between Ϫ70 and ϩ40 mV. Tail current amplitude was measured as its initial value after the voltage pulse. Activation and inactivation time constants were fitted using custom software. Data are expressed as means Ϯ SE. Intergroup differences were analyzed by analysis of variance followed by Duncan's multiple range test or Student's t-test as appropriate. A value of P Ͻ 0.05 was considered statistically significant.
RESULTS
Properties of I K V of rat mesenteric artery smooth muscle. Whole cell patch-clamp recordings from rat mesenteric artery smooth muscle cells revealed the presence of I K V , which was activated by depolarizing steps to potentials more positive than approximately Ϫ30 mV. The current activated relatively slowly, and under control conditions little or no inactivation was observed during 400-ms pulses. The steady-state activation voltage relation for I K V was obtained by measuring tail currents at Ϫ20 mV after a range of depolarizing steps from Ϫ60 mV (Fig. 1A) . Steady-state inactivation curves were obtained by varying the holding potential and measuring the current induced by a step to ϩ20 mV (Fig. 1B) . Plots of the mean steady-state activation and inactivation curves from six cells were fitted with a Boltzmann distribution, giving voltages for half-maximal activation and inactivation (V 1/2 ) of Ϫ3.5 and Ϫ33.9 mV, respectively. Examination of the conductance data and Boltmann curves shown in Fig. 1 indicates a significant conductance due to K V channels above Ϫ40 mV, which is within the physiological range of membrane potential in arterial smooth muscle (18, 26) .
ANG II inhibits I K V . The effect of ANG II on I K V is shown in Fig. 2 . Depolarizing steps to ϩ20 mV were applied for 400 ms every 1 min from a holding potential of Ϫ60 mV to follow the time course of the effect of ANG II. The runup of I K V over the first 4 min is most likely due to the presence of Mg-ATP in the pipette solution leading to PKA-mediated phosphorylation (1). All experiments were performed only after a stable amplitude of I K V was recorded after runup current. ANG II induced a progressive decline in the amplitude of the outward current measured at the end of the depolarizing steps. The effect of ANG II was maximal after a period of 5-20 min and was reversible upon washout. Similar results were obtained from nine other cells. To test whether ANG II affected I K V in a voltage-dependent manner, a series of voltage pulses was applied (from Ϫ70 and ϩ40 mV in 10-mV intervals), and the currents at the end of the 400-ms pulses were compared before and after application of 100 nM ANG II (Fig. 2, C and D) . ANG II induced a significant and similar decrease in the amplitude of steady-state and tail currents at all potentials where accurate measurements could be obtained. An interesting feature of the ANG II effect was a speeding up of I K V activation and the induction of inactivation (see below). Steady-state activation parameters were obtained from tail currents at Ϫ20 mV after the test pulses. The V 1/2 value for activation in the presence of ANG II was Ϫ7.8 mV compared with the control value of Ϫ3.5 mV (see above), suggesting that ANG II had no significant effect on the voltage dependence of the steady-state activation of I K V . A similar result was obtained by Clément-Chomienne et al. (5) for ANG II-induced inhibition of I K V in rabbit portal vein cells.
Losartan inhibits the action of ANG II. At least two types of ANG II receptors are currently known, AT 1 and AT 2 (37) . The selective AT 1 antagonist losartan has been shown to be effective at inhibiting the reduction in blood flow caused by ANG II (35) . To investigate whether this type of receptor is involved in K V channel inhibition in rat arterial muscle, we tested the effect of ANG II in the presence of 1 M losartan. Figure 3 , A and B, shows that 10-min pretreatment with losartan Fig. 2 . Inhibition of IK V by angiotensin II (ANG II). A: representative current recordings obtained before (control), during (ANG II), and after (wash) the addition of 100 nM ANG II as indicated. Pulses from Ϫ60 to ϩ20 mV were applied at 1-min intervals during this experiment. B: steady-state outward current amplitude measured at the end of the pulses shows the time course of the effect of ANG II. C: example of the effect of ANG II over a range of depolarizations in 10-mV steps to the levels indicated on the voltage protocol. D: resulting current-voltage (I-V) curves obtained by measuring the current at the end of the pulse in control (F) and in the presence of 100 nM ANG II (E). E: plot of mean tail current amplitudes for control (F; ϮSE) and in the presence of 100 nM ANG II (E; ϮSE) from 10 cells. The solid lines are fits to the Boltzmann distribution,
where V1/2 is the voltage at which the conductance, G, is half the maximal conductance Gmax and k is a factor determining how steeply G changes the voltage. The values for V1/2 and k were Ϫ3.5 and 7.4 mV for control (same data as in Fig. 1C ) and Ϫ7.8 and 6.7 mV in 100 nM ANG II, respectively. Vh, holding potential. C: plots of steady-state activation and inactivation against membrane potential (Vm). For activation, the tail current amplitude was normalized to the maximum tail current (F; ϮSE, n ϭ 10), and for inactivation the current amplitudes at ϩ20 mV were normalized to the maximum current (E; ϮSE, n ϭ 4). The solid lines are fits to the Boltzmann distribution (see Fig. 2) , with values for half-maximal voltage potentials (V1/2) and k of Ϫ3.5 and 7.4 mV for activation and Ϫ33.9 and Ϫ8.8 mV for inactivation.
prevented I K V inhibition by ANG II, indicating that the AT 1 receptor mediates this effect.
ANG II is still effective in the presence of iberiotoxin. Our recording conditions (low intracellular [Ca 2ϩ ] and only moderate depolarizations) were designed to minimize the activation of BK Ca channels, which are prevalent in this tissue (32) . To test for a possible involvement of BK Ca channels, we used iberiotoxin (IbTX), a potent and selective inhibitor of these channels in smooth muscle (11) . A series of recordings from a cell under control conditions, in the presence of 100 nM IbTX, and in the presence of both IbTX and ANG II is shown in Fig. 3C . At voltages above ϩ10 mV there is a slight reduction in current with IbTX, indicating that a small component of current flows through BK Ca channels. Application of ANG II, however, still caused a marked reduction in I K V in the presence of IbTX. The mean I-V curve, normalized to the control current at ϩ40 mV, from four cells is shown in Fig. 3D . The mean fractional reduction of the IbTX-resistant current by ANG II was 0.49 Ϯ 0.15 at ϩ40 mV, which is a similar reduction to that seen in the absence of IbTX. These results show that the major effect of ANG II that we describe here is on I K V rather than on BK Ca channels, even in the absence of IbTX.
ANG II alters the kinetics of I K V . Application of ANG II accelerated the activation process and caused a partial time-dependent inactivation of I K V during a 400-ms pulse. The relative amount of the inactivating component varied between cells. To quantify these alterations in kinetics, we fitted exponential functions to activation and inactivation in the absence and pres- ence of ANG II and to inactivation in the presence of ANG II only, because in its absence I K V did not inactivate during the duration of the pulses. Examples of the currents induced by pulses to ϩ40 mV showing the alteration in activation and inactivation induced by ANG II and of the exponential fits are shown in Fig. 4 , A and C. Plots of the activation and inactivation time constants are shown in Fig. 4, B and D, respectively. The mean activation time constants at ϩ40 mV were 29.8 Ϯ 6.2 and 12.2 Ϯ 1.8 ms (n ϭ 5) in the absence and presence of 100 nM ANG II, respectively. The mean inactivation time constant induced by ANG II was 85.6 Ϯ 6.2 ms (n ϭ 5).
I K V is reduced by DiC8 and Rp-cAMPS. The signal transducation events stimulated by binding of ANG II to AT 1 receptors include activation of PLC, activation of PKC, and inhibition of adenylyl cyclase (2, 9, 12, 28, 35, 37). We therefore investigated the possibility that the ANG II-induced inhibition of I K V occurred by a dual mechanism involving activation of PKC and inhibition of background PKA activity.
As shown in Fig. 5 , A and B, application of 2 M DiC8, a membrane-permeant analog of DAG, significantly reduced I K V . It is also evident in this example that DiC8 caused a marked inactivation of the current. This is consistent with activation of PKC mediating at least part of the ANG II-induced inhibition of I K V . ANG II-induced inhibition of I K V via PKC has also been reported in rabbit portal vein smooth muscle (5), although in that tissue no inactivation was seen. Their results, however, do not provide any evidence for the involvement of the adenylyl cyclase-PKA system in the inhibitory action of ANG II. Because activation of adenylyl cyclase, and so PKA, has been shown to activate I K V (1), it is possible that inhibition of background adenylyl cyclase activity mediates part of the inhibitory action of ANG II on I K V , as we have shown to be the case for ANG II-induced inhibition of K ATP channels (15) . To investigate this possibility, we inhibited PKA by application of the cAMP analog Rp-cAMPS, which inactivates PKA by binding to its regulatory subunit (31) . Figure 5 , C and D, shows that 100 M Rp-cAMPS inhibited I K V significantly. DiC8 (2 M) reduced I K V at ϩ40 mV, normalized to its value before addition of the agent, to 0.32 Ϯ 0.03 of control value (n ϭ 12), whereas 100 M Rp-cAMPS reduced I K V to 0.48 Ϯ 0.03 of control value (n ϭ 8; Fig. 5E ). The change in kinetics induced by DiC8 is similar to that produced by ANG II. Application of DiC8 induced a similar change in the kinetics of I K V as did ANG II. We fitted both activation and inactivation time courses with a single exponential function, as for the ANG II data. Plots of the activation time constants in the presence and absence of DiC8 and of the inactivation time constants in the presence of DiC8 are shown in Fig. 6, A and B, respectively . The values are comparable with those shown in Fig. 4 for the effect of ANG II. At ϩ40 mV, activation time constants were 19.3 Ϯ 2.5 and 8.0 Ϯ 1.3 ms (n ϭ 4) in control and 2 M DiC8, respectively. ANG II (100 nM) and DiC8 (2 M) both reduced the activation time constants to 41% of the control value. The inactivation time constant in the presence of 2 M DiC8 was 67.5 Ϯ 11.9 ms (n ϭ 4), which was again comparable with that measured in the presence of ANG II. We considered the possibility that DiC8 and ANG II, through activation of PKC, were activating an additional A-type K ϩ channel. Under control conditions, an A-type K ϩ current was not seen, even when the holding potential was increased to Ϫ90 or Ϫ100 mV to remove any possible steady-state inactivation, which is characteristic of A-type currents (see Fig. 1B, for example) . Because A-type currents usually have a relatively negative steady-state inactivation curve (4, 6), we were interested in measuring this parameter for the current in the presence of DiC8. We obtained the steady-state inactivation curve by varying the holding potential, measuring the peak current induced by a step to ϩ20 mV, and normalizing this to the maximum current measured (Fig. 6, C and D) . V 1/2 for steady-state inactivation in the presence of DiC8 was Ϫ33.3 mV, almost identical to that in its absence (Ϫ33.9 mV), arguing against the possibility that activation of PKC induces an A-type current.
The combination of PKC and PKA inhibitors blocks ANG II-induced inhibition. To test the relative contribution of PKA inhibition and PKC activation to the inhibition of I K V by ANG II, we pretreated smooth muscle cells with either PKC-IP or PKA-IP. PKA-IP (5 M) was applied intracellularly by inclusion in the patch pipette solution, and PKC-IP (100 M) was applied extracellularly in its myristoylated cell-permeant form at least 10 min before recording. We examined the specificity of these inhibitors previously by testing their effectiveness at inhibiting dibutyryl cAMPinduced activation of K ATP currents (15) . Although either PKC-IP or PKA-IP decreased the effect of ANG II, they failed to induce complete inhibition of the ANG II effect (Fig. 7) . However, after pretreatment with both PKC-IP and PKA-IP, ANG II no longer affected the amplitude or kinetics of I K V . These results suggest that the mechanism for inhibition of I K V by ANG II occurs through a dual pathway, simultaneous activation of PKC and inhibition of PKA.
PKC-⑀ is the subtype involved in inhibition by ANG II. The Ca 2ϩ
-dependent isoforms of PKC, PKC-␣ and PKC-␤, and the Ca 2ϩ -independent isoforms, PKC-⑀ and PKC-, have been shown to be expressed in vascular smooth muscle (5, 8, 23) . Although previous reports (5, 20) suggest that the isoform involved in the ANG II pathway is Ca 2ϩ independent, the PKC isoform that is involved in K V channel inhibition is not known.
To address this question, we examined the effect of ANG II on I K V in the presence of Gö6979 (1 M), an indolocarbazole that specifically inhibits Ca 2ϩ -dependent PKC isoforms (24), together with PKA-IP (5 M) to remove basal PKA activity. The amplitude of I K V was significantly reduced by ANG II under these conditions (Fig. 8) , suggesting that a Ca 2ϩ -independent PKC isoform is involved in this inhibition. Although two Ca 2ϩ -independent PKC isoforms, PKC-⑀ and PKC-, are present in smooth muscle, PKC-⑀ is more likely to be involved in the regulation of K V channels by ANG II because PKC-is insensitive to DAG analogs (29) and the DAG analog DiC8 can inhibit the current (Fig. 5A) . Fig. 6 . Change in kinetics produced by DiC8. A: plot of mean (ϮSE, n ϭ 4) activation time constants in control (F) and in the presence of 2 M DiC8 (E). B: plot of mean (ϮSE, n ϭ 4) inactivation time constants in the presence of 2 M DiC8. C: currents produced by depolarizing pulses to ϩ20 mV from different Vh ranging from Ϫ100 to Ϫ20 mV in control and in the presence of 2 M DiC8. D: currents at ϩ20 mV in the presence of DiC8, normalized to the maximum current, plotted against Vh (means Ϯ SE, n ϭ 4). The solid line shows the fit to a Boltzmann distribution, giving V1/2 of Ϫ33.3 and k of Ϫ9.9 mV. The dashed line is the curve for the control currents and is the same as shown in Fig. 1 .
We therefore examined the effect of pretreatment with PKC-⑀ translocation inhibitor peptide (40 M) in the presence of 5 M PKA-IP (as before). The effect of ANG II on I K V under these conditions was completely abolished (Fig. 8) , as expected if its effects occurred solely through PKC-⑀.
The PKA catalytic subunit directly activates K V channels. If part of the inhibition of I K V by ANG II is through a reduction in PKA activity, then, unless basal channel activation by PKA is maximal, increasing phosphorylation by PKA should enhance I K V . We tested this by applying the catalytic subunit of PKA to excised inside-out patches and analyzed the ensemble currents produced from ϳ50 consecutive depolarizing pulses to ϩ60 mV first in the absence and then in the presence of the PKA catalytic subunit. In five of eight patches tested, the PKA catalytic subunit (100 U/ml) increased the activity of single K V channels. Examples of individual traces and their ensemble averages obtained in the absence and presence of the PKA catalytic subunit are shown in Fig. 9 .
DISCUSSION
In this study, the effect of ANG II on whole cell I K V of enzymatically isolated rat mesenteric artery smooth muscle cells was investigated using patch-clamp techniques. We constrained our recording conditions to minimize current flow through channels other than K V channels by buffering internal Ca 2ϩ with 10 mM EGTA and using low external [Ca 2ϩ ] (0.1 mM) to minimize changes in internal [Ca 2ϩ ]. An internal ATP of 3 mM ensured very low activity of K ATP channels. Our results show for the first time that ANG II, by binding to the AT 1 receptor, reduced I K V through a dual signaling mechanism involving not only activation of PKC but also inhibition of PKA. Furthermore, we provide evidence that the PKC component of the action of ANG II is mediated by the ⑀-isozyme.
Signaling mechanisms involved in inhibition of I K V by ANG II. ANG II has been shown to modulate several types of ionic conductance in vascular smooth muscle cells and appears to do so by a number of different pathways. Thus ANG II inhibits BK Ca channels by a PKC-independent mechanism in cultured porcine coronary artery smooth muscle cells (25) , whereas the mechanism by which ANG II activates a nonselective cation channel in the rabbit ear artery is not known but is likely to occur without a rise in D-myo-inositol (1, 4, 5) trisphosphate [Ins(1,4,5)P 3 ] (17). We have recently shown that ANG II inhibits K ATP channels through a dual mechanism involving activation of PKC and inhibition of PKA (15) . In rabbit portal vein smooth muscle cells, ANG II induces inhibition of I K V , which is associated with activation of PKC (5). This effect was abolished by the PKC inhibitors calphostin C and chelerythrine (5). However, in arterial smooth muscle, we find that the effect of ANG II on I K V is not completely blocked by PKC-IP but is abolished only in the presence of both PKC-IP and PKA-IP. The discrepancy between their findings and ours could be due to a difference in the K V channels involved. The V1⁄2 of I K V in this study was Ϫ3.5 mV compared with Ϫ24.6 mV as measured by Clément-Chomienne et al. (5), suggesting that the K ϩ channels found in the rabbit portal vein Fig. 9 . PKA activation of K ϩ channels in an inside-out patch. A: example traces from an inside-out patch pulsed from Ϫ80 to ϩ60 mV. This patch appeared to contain only one active channel. Application of 100 U/ml PKA catalytic subunit increased the open probability of these channels. B: ensemble averages generated from 47 sweeps both in control and in the presence of the PKA catalytic subunit. are composed of different Kv subunits to those found in rat artery smooth muscle. We obtained recordings of 20-pS channels corresponding to K V channels from inside-out patches that were activated by application of the catalytic subunit of PKA (with MgATP), as shown in Fig. 9 . A channel with similar properties (termed K DR1 ) that has been described in colonic smooth muscle was also found to be activated by PKA (19) .
To investigate the identity of the PKC isoform involved in the action of ANG II, we used isoform-selective PKC inhibitors in the presence of PKA-IP to abolish the PKA component of ANG II action. Gö6979, an inhibitor of Ca 2ϩ -dependent PKC isoforms, did not abolish the effect of ANG II. A Ca 2ϩ -independent isoform, PKC-⑀, has been shown to be translocated in response to ANG II stimulation of cultured canine pulmonary artery smooth muscle cells (7) . In the present study, we showed that the PKC-⑀ translocation inhibitor peptide abolished the PKC component of the ANG II effect on I K V , indicating that PKC-⑀ is the isoform involved in the ANG II-induced inhibition of I K V .
The change in kinetics of I K V induced by ANG II. An intriguing effect of ANG II on I K V was a change in kinetics. In many cells, ANG II produced a significant inactivation of I K V such that the current now resembled an A-type K ϩ current. This effect was also very pronounced when DiC8 was applied to the cells. In cells pretreated with PKC-IP, however, very little or no inactivation was detected in the presence of ANG II, even though ANG II reduced the total K ϩ current. A similar change in kinetics was observed by Smirnov and Aaronson (33) when they applied 1-oleoyl-2-acetylsn-glycerol (OAG) to rat pulmonary arterial myocytes. In control conditions, we could not detect a fast inactivating component of I K V even when the holding potential was set to Ϫ100 mV to remove any possible steadystate inactivation known to occur with A-type currents (4). It is possible that ANG II (and DiC8) activates an A-type current that is quiescent under normal conditions. Given the similarity of the inactivation curves of the inactivating and control components shown in Fig.  6 , another possibility is a phosphorylation-dependent interaction of K V ␤-subunits with the ␣-subunits involved in generating the I K V seen in our experiments. Kwak et al. (21) recently reported protein kinase-induced interactions between recombinant K V channel ␣-and ␤-subunits, raising the possibility that this might also occur for native channels. Such an effect could explain the similarity between the steady-state inactivation parameters of control current and the inactivating current seen with ANG II or DiC8.
The physiological role of inhibition of I K V by ANG II. In addition to increasing intracellular Ca 2ϩ of vascular smooth muscle by activating membrane Ca 2ϩ -permeable channels and causing intracellular Ca 2ϩ release, ANG II inhibits several K ϩ channels, including K ATP , BK Ca , and K V channels. Such K ϩ channel inhibition will serve to enhance the depolarizing actions of ANG II, increasing voltage-dependent Ca 2ϩ entry and vasoconstriction. Under normal conditions, K V channels, through their steep voltage dependence of activation, might be expected to provide a negative feedback system that tends to limit the magnitude of depolarization. Inhibition of K ATP channels by ANG II would depolarize the cell, and the simultaneous inhibition of K V channels would decrease the limit on depolarization imposed by K V channels, thus allowing greater depolarization. In the present study, we were concerned with the mechanisms by which ANG II inhibits a particular K ϩ channel, K V . We therefore buffered intracellular Ca 2ϩ to a low level in our experiments to minimize the activation of Ca 2ϩ -activated channels, and thus we have not investigated a possible direct inhibition of K V channels by intracellular Ca 2ϩ , as reported by Gelband and Hume (10) for canine renal artery K V channels. However, if such Ca 2ϩ -dependent inhibition does occur, it would enhance the kinasedependent inhibition of K V channels that we describe here. Clearly, inhibition of K V channels forms just one component of the complex network of signaling pathways by which ANG II leads to depolarization, increased intracellular Ca 2ϩ , and vasoconstriction. Because of the interdependence of several of these pathways, dissection of the relative functional importance of any single component is a daunting task. However, the fact that ANG II has been shown to inhibit each of the known K ϩ currents of vascular smooth muscle, with the exception of inward rectifiers, suggests that K ϩ channel inhibition is likely to make an important contribution to its vasoconstrictor effects.
